News | November 11, 2021
Hester Biosciences to acquire 50 % stake in Thrishool Exim, Tanzania
The consideration for the acquisition is US $ 2.25 million
The consideration for the acquisition is US $ 2.25 million
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Acute therapies continue to report strong growth compared to chronic ones.
Support from DFC will help produce one billion vaccine doses by the end of 2022
Key takeaways of recent quarter & conference call highlights
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
The company plans to raise US $ 15 million
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
